<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Radiat Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Radiat Oncol</journal-id><journal-title-group><journal-title>Clinical and Translational Radiation Oncology</journal-title></journal-title-group><issn pub-type="epub">2405-6308</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29594241</article-id><article-id pub-id-type="pmc">5862670</article-id><article-id pub-id-type="publisher-id">S2405-6308(17)30087-3</article-id><article-id pub-id-type="doi">10.1016/j.ctro.2017.11.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ashton</surname><given-names>M.</given-names></name><email>miranda.ashton@glasgow.ac.uk</email><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>O'Rourke</surname><given-names>N.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Macleod</surname><given-names>N.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Laird</surname><given-names>B.</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Stobo</surname><given-names>J.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>C.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Alexander</surname><given-names>L.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Franks</surname><given-names>K.</given-names></name><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>K.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Currie</surname><given-names>S.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Valentine</surname><given-names>R.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Chalmers</surname><given-names>A.J.</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref></contrib></contrib-group><aff id="af005"><label>a</label>Institute of Cancer Sciences, University of Glasgow, UK</aff><aff id="af010"><label>b</label>Beatson West of Scotland Cancer Centre, Glasgow, UK</aff><aff id="af015"><label>c</label>Edinburgh Cancer Centre, UK</aff><aff id="af020"><label>d</label>Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK</aff><aff id="af025"><label>e</label>St James&#x02019; Institute of Oncology, Leeds, UK</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK.Beatson West of Scotland Cancer Centre1053 Great Western RoadGlasgowG12 0YNUK <email>miranda.ashton@glasgow.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>21</day><month>11</month><year>2017</year></pub-date><volume>8</volume><fpage>45</fpage><lpage>49</lpage><history><date date-type="received"><day>13</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">A randomised phase II trial of radiotherapy dose escalation for pain control in MPM.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">Comparison of 2 hypofractionated regimes (20&#x0202f;Gy/5# and 36&#x0202f;Gy/6#).</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">Highly conformal radiotherapy techniques used to aid safe dose escalation.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0020">Primary outcome: pain control at week 5 at radiotherapy site.</p></list-item><list-item id="o0030"><label>&#x02022;</label><p id="p0030">Recruitment target: 112 patients from 10 to 15 UK centres.</p></list-item></list></p></abstract><abstract id="ab010"><p>SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20&#x0202f;Gy/5#) or dose escalated treatment (36&#x0202f;Gy/6#) will be delivered using advanced radiotherapy techniques and pain responses will be compared at week 5. Data will guide optimal palliative radiotherapy in MPM.</p></abstract></article-meta></front><body><sec id="s0005"><title>Introduction</title><p id="p0035">Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer with a dismal prognosis. <xref rid="b0005" ref-type="bibr">[1]</xref> As there are no curative options, management focuses on palliation. Pain is the most common symptom <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>. It is typically dull and diffuse and worsens throughout the course of the disease <xref rid="b0020" ref-type="bibr">[4]</xref>. Aetiology is multifactorial, often including neuropathic and bone related components which can be difficult to control, and patients are often on a variety of analgesics with inadequate relief <xref rid="b0025" ref-type="bibr">[5]</xref>.</p><p id="p0040">Radiotherapy for pain control is recommended by the British Thoracic Society as a component of standard care <xref rid="b0020" ref-type="bibr">[4]</xref>. Nevertheless, a systematic review conducted in 2014 revealed that only Level 3 evidence was available to support this practice and highlighted the need for robust and accurate symptom response data <xref rid="b0030" ref-type="bibr">[6]</xref>. We therefore conducted the SYSTEMS study, a multicentre, single arm phase II study of conventional dose palliative radiotherapy in MPM (20&#x0202f;Gy in 5#), delivered using parallel opposing beams. The first prospective study to use validated outcome measures to assess pain in MPM, SYSTEMS recruited 40 patients over 18&#x0202f;months and reported clinically significant pain responses 5&#x0202f;weeks after radiotherapy in one third of patients, with minimal toxicity <xref rid="b0035" ref-type="bibr">[7]</xref>.</p><p id="p0045">We hypothesised that a higher radiation dose would achieve clinically meaningful pain responses in a greater proportion of patients and might extend analgesia duration. We will test this hypothesis in SYSTEMS-2, which will compare the effects of dose escalated and standard dose radiotherapy on pain control in MPM patients. Recognising that dose escalation might increase toxicity, which could negate any palliative benefit of the treatment, we will utilise advanced radiotherapy delivery techniques, predominantly intensity modulated radiotherapy (IMRT), to facilitate dose escalation to tumour volumes whilst maintaining acceptable doses to normal tissues.</p><p id="p0050">Responses to radiotherapy doses can be predicted using the &#x003b1;/&#x003b2; ratio of the tumour. Whilst there are little data on which to estimate the &#x003b1;/&#x003b2; ratio of MPM, its relatively low proliferation rate, mesenchymal origin and apparent radioresistance are suggestive of a low &#x003b1;/&#x003b2; value <xref rid="b0035" ref-type="bibr">[7]</xref>. For this reason, and to allow palliative treatment to be delivered succinctly, a hypofractionated regime of 36&#x0202f;Gy in 6 fractions over 2&#x0202f;weeks has been selected for the dose escalation arm of SYSTEMS-2.</p><sec id="s0010"><title>Methods/study design</title><p id="p0055">SYSTEMS-2 was developed through multidisciplinary collaboration between the Beatson West of Scotland Cancer Centre, Edinburgh Cancer Research Centre and the Cancer Research UK Clinical Trials Unit Glasgow. The study is sponsored by NHS Greater Glasgow and Clyde and the University of Glasgow (GN13ON388). Ethical approval was granted from the National Research Ethics Committee on 19th January 2016 (REC number 15/SS/0225). The study complies with Research Governance Framework for Health and Community Care, the British Good Clinical Practice regulations and the Declaration of Helsinki. The study is registered on the publically available ISRCTN database and is badged by the National Institute for Health Research.</p><p id="p0060">Funding is provided by the June Hancock Mesothelioma Research Fund and Beatson Cancer Charity. The translational sample collection is funded by Beatson Cancer Charity, and Slater and Gordon&#x02019;s Health Projects and Research Fund.</p><p id="p0065">SYSTEMS-2 is a randomised, phase II, multicentre trial comparing two hypofractionated schedules of radiotherapy for pain control in MPM: dose escalated (36&#x0202f;Gy in 6 fractions over 2&#x0202f;weeks) and standard (20&#x0202f;Gy in 5 fractions over 1&#x0202f;week). 112 patients in whom radiotherapy is clinically indicated for MPM associated pain will be enrolled.</p><p id="p0070">Inclusion criteria:<list list-type="simple" id="l0010"><list-item id="o0035"><label>&#x02022;</label><p id="p0075">Histological/MDT diagnosis of MPM</p></list-item><list-item id="o0040"><label>&#x02022;</label><p id="p0080">Performance status 0&#x02013;2 (ECOG)</p></list-item><list-item id="o0045"><label>&#x02022;</label><p id="p0085">Predicted life expectance&#x0202f;&#x0003e;12&#x0202f;weeks</p></list-item><list-item id="o0050"><label>&#x02022;</label><p id="p0090">Contrast enhanced CT scan within 8&#x0202f;weeks of starting radiotherapy</p></list-item><list-item id="o0055"><label>&#x02022;</label><p id="p0095">Worst pain score&#x0202f;&#x02265;4/10 after analgesia optimisation</p></list-item><list-item id="o0060"><label>&#x02022;</label><p id="p0100">Ability to provide written informed consent</p></list-item><list-item id="o0065"><label>&#x02022;</label><p id="p0105">Willingness to comply with study procedures</p></list-item><list-item id="o0070"><label>&#x02022;</label><p id="p0110">Radiotherapy plan compatible with the dose escalated arm prior to randomisation</p></list-item></list></p><p id="p0115">Exclusion criteria:<list list-type="simple" id="l0015"><list-item id="o0075"><label>&#x02022;</label><p id="p0120">Patients receiving anti-cancer therapy within 4&#x0202f;weeks of study entry or who are planned for anti-cancer therapy within 6&#x0202f;weeks of radiotherapy</p></list-item><list-item id="o0080"><label>&#x02022;</label><p id="p0125">Prior radiotherapy where there is concern that the proposed treatment volume would overlap with a previously irradiated area. This does not include patients who have received superficial photon or electron therapy to drain sites</p></list-item><list-item id="o0085"><label>&#x02022;</label><p id="p0130">Psychotic disorders/cognitive impairment</p></list-item><list-item id="o0090"><label>&#x02022;</label><p id="p0135">Co-existing lung tumours</p></list-item><list-item id="o0095"><label>&#x02022;</label><p id="p0140">Pregnant/breastfeeding</p></list-item><list-item id="o0100"><label>&#x02022;</label><p id="p0145">Patients of child-bearing potential, unwilling to use 2 effective methods of contraception.</p></list-item></list></p></sec><sec id="s0015"><title>Study objectives and endpoints</title><p id="p0150">Primary objective: to establish whether dose escalated, hypofractionated radiotherapy increases the proportion of MPM patients experiencing a clinically significant improvement in pain at the site of radiotherapy at week 5, compared with standard radiotherapy. Pain will be assessed using the Brief Pain Inventory (BPI), a multi-dimensional pain assessment tool which has been extensively validated in both cancer and non-cancer patients <xref rid="b9000" ref-type="bibr">[8]</xref>, <xref rid="b9005" ref-type="bibr">[9]</xref>. A responder will be any patient who has at least a 2 point drop in the &#x02018;worst pain score&#x02019; component of the BPI, from baseline to week 5.</p><p id="p0155">Secondary objectives:<list list-type="simple" id="l0020"><list-item id="o0105"><label>1.</label><p id="p0160">Acute toxicity (end of the radiotherapy and weeks 5 and 9)</p></list-item><list-item id="o0110"><label>2.</label><p id="p0165">Overall BPI score and BPI components of average pain, intensity subscale and functional interference subscale (weeks 5 and 9)</p></list-item><list-item id="o0115"><label>3.</label><p id="p0170">Radiological response (week 9)</p></list-item><list-item id="o0120"><label>4.</label><p id="p0175">Overall survival (OS)</p></list-item><list-item id="o0125"><label>5.</label><p id="p0180">Quality of life (QoL) at weeks 5 and 9 (assessed by EORTC QLQ-C3O and LC13).</p></list-item></list></p><p id="p0185">Exploratory endpoints will include change in strong opioid use, health related QOL at week 9 and translational biomarker studies.</p><p id="p0190">In order to allow the effects of the radiotherapy to be determined accurately, patients must have their analgesia optimised prior to randomisation and if necessary should be reviewed by their local palliative care team.</p></sec><sec id="s0020"><title>Radiotherapy details</title><p id="p0195">Radio-opaque markers should be used to demarcate painful sites at the time of CT acquisition (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Wire markers denoting the site of pain to aid radiotherapy planning.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0200">IMRT is recommended for radiotherapy planning and delivery; however, if this technology is unavailable, 3D conformal techniques are acceptable. The clinical target volume (CTV) will be outlined on each slice and should include the area(s) demarcated by wire markers. If there is neuropathic pain, the relevant nerve root should be included. The planning target volume (PTV) will be formed by adding a 1&#x02013;2&#x0202f;cm margin around the CTV. Relevant organs at risk (OARs) should be outlined on each CT slice, depending on tumour position (<xref rid="t0005" ref-type="table">Table 1</xref>).<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Dose constraints for SYSTEMS-2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Structure</th><th>Constraint</th><th>Maximum dose</th><th>Indication for delineation</th></tr></thead><tbody><tr><td colspan="4"><bold><italic>OARs</italic></bold></td></tr><tr><td rowspan="3">Contralateral lung</td><td>&#x0003c;5%</td><td>V20&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>&#x0003c;50%</td><td>V10&#x0202f;Gy</td><td/></tr><tr><td>&#x0003c;70%</td><td>V5&#x0202f;Gy</td><td/></tr><tr><td>Oesophagus</td><td>Dmax (0.5&#x0202f;cc)</td><td>30&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>Spinal canal</td><td>Dmax (0.5&#x0202f;cc)</td><td>27&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>Trachea and proximal bronchus</td><td>Dmax (0.5&#x0202f;cc)</td><td>36&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>Heart</td><td>Dmax (0.5&#x0202f;cc)</td><td>36&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>Liver</td><td>Mean Liver Dose</td><td>16&#x0202f;Gy</td><td>Low lying right sided tumours where&#x0202f;&#x0003e;700&#x0202f;cc of liver scanned</td></tr><tr><td>Kidneys (individual and combined)</td><td>Mean kidney dose</td><td>10&#x0202f;Gy</td><td>Low lying tumours</td></tr><tr><td>If solitary kidney or if one kidney mean dose&#x0202f;&#x0003e;&#x0202f;10&#x0202f;Gy</td><td>&#x0003c;45%</td><td>V10&#x0202f;Gy</td><td>Low lying tumours</td></tr><tr><td>Stomach</td><td>Dmax (0.5&#x0202f;cc)</td><td>30&#x0202f;Gy</td><td>Low lying left sided tumours</td></tr><tr><td>Great Vessels</td><td>Dmax (0.5&#x0202f;cc)</td><td>36&#x0202f;Gy</td><td>Any tumour position</td></tr><tr><td>Small bowel</td><td>Dmax (0.5&#x0202f;cc)</td><td>30&#x0202f;Gy</td><td>Low lying tumours</td></tr><tr><td>Ipsilateral Brachial Plexus</td><td>Dmax (0.5&#x0202f;cc)</td><td>36&#x0202f;Gy</td><td>PTV above T2</td></tr><tr><td>Large bowel</td><td>Dmax (0.5&#x0202f;cc)</td><td>30&#x0202f;Gy</td><td>Low lying tumours</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4"><bold><italic>PTV</italic></bold></td></tr><tr><td>Minimum</td><td>D98%</td><td>&#x0003e;95%</td><td/></tr><tr><td>Median</td><td>D50%</td><td>100%</td><td/></tr><tr><td>Maximum</td><td>D2%</td><td>&#x0003c;107%</td><td/></tr></tbody></table></table-wrap></p><p id="p0205">While IMRT provides an effective way of manipulating dose distribution, the inverse planning process may allow dose to be &#x02018;dumped&#x02019; in regions with no maximum specified dose. Therefore, OARs must be outlined and allocated an appropriate constraint.</p><p id="p0210">There are few data to support OAR dose constraints for hypofractionated regimes, particularly in the palliative setting. However, relevant data is available for stereotactic ablative radiotherapy, where large doses are delivered in small numbers of fractions to limited volumes, often with radical intent <xref rid="b0040" ref-type="bibr">[10]</xref>, <xref rid="b0045" ref-type="bibr">[11]</xref>. These data have been used to guide development of dose constraints for SYSTEMS-2 (<xref rid="t0005" ref-type="table">Table 1</xref>).</p><p id="p0215">PTV coverage should not be compromised unless there are clinical concerns that dose(s) to OAR(s) would cause unacceptable acute toxicity. In situations where dose constraints cannot be met, it is acceptable to reduce the total dose to 30&#x0202f;Gy in 5 fractions over 2&#x0202f;weeks.</p><p id="p0220">Dose will be prescribed using an isocentric technique. Plans should be normalised with 100% prescription to the target volume median dose in accordance with ICRU83. Centres unable to prescribe to the median dose can alternatively prescribe to the mean dose. Anticipated PTV coverage parameters are shown in <xref rid="t0005" ref-type="table">Table 1</xref>.</p><p id="p0225">To prevent bias in treatment planning and target volume delineation, radiotherapy planning will occur before randomisation. All patients will initially be planned for the dose escalated arm and any patient randomised to standard treatment will be re-planned prior to the first fraction. Any patient for whom a dose-escalated plan is not achievable will be ineligible.</p><p id="p0230">Radiotherapy quality assurance will be implemented by the National Radiotherapy Trials QA Group.</p><p id="p0235">Acute radiation toxicities should be managed with supportive medicines as per local policy. Timings and dosages of all analgesics should be recorded. In the event of a pleuritic pain flare, a short course of high dose steroids is advised.</p></sec><sec id="s0025"><title>Follow up</title><p id="p0240">The follow up schedule is shown in <xref rid="f0010" ref-type="fig">Fig. 2</xref>. After 26&#x0202f;weeks, 2&#x0202f;monthly survival assessments will be conducted by the recruiting centre.<fig id="f0010"><label>Fig. 2</label><caption><p>Schedule of events.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0245">Central radiological review will be led by a Glasgow based consultant radiologist, blinded to the delivered radiotherapy dose. Appropriate target lesions will be selected on the basis of the baseline CT and radiotherapy plan. Response at week 9 will be reported to Modified RECIST criteria.</p></sec><sec id="s0030"><title>Safety reporting</title><p id="p0250">All Adverse Events (AE) must be recorded in full and include the event nature, start and stop dates, severity (graded to CTCAEv4), seriousness and relationship to radiotherapy.</p><p id="p0255">As the safety profile of radiotherapy is well known, only events that meet the criteria of a Serious Adverse Event (SAE), are directly related to the administration of radiotherapy and are not listed as expected side effects of radiotherapy (<xref rid="t0010" ref-type="table">Table 2</xref>) require reporting as SAEs.<table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Expected side effects of radiotherapy.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Pulmonary haemorrhage</td><td>Pneumonitis</td></tr><tr><td colspan="2"><hr/></td></tr><tr><td>Oesophageal candidiasis</td><td>Dermatitis radiation</td></tr><tr><td>Anaemia</td><td>Pulmonary fistula</td></tr><tr><td>White blood cell decreased</td><td>Carbon monoxide diffusing capacity decreased</td></tr><tr><td>Neutrophil count decreased</td><td>Forced expiratory volume decreased</td></tr><tr><td>Nausea</td><td>Vital capacity abnormal</td></tr><tr><td>Vomiting</td><td>Cardiac toxicity (pericardial disease or myocardial infarction)</td></tr><tr><td>Constipation</td><td>Spinal cord toxicity</td></tr><tr><td>Fatigue</td><td>Late oesophageal stricture</td></tr><tr><td>Febrile neutropenia</td><td>Late radiation fibrosis</td></tr><tr><td>Neutropenic sepsis</td><td>RT induced rib fracture</td></tr><tr><td>Lung infection</td><td>Late malignancy within the radiation field</td></tr><tr><td>Oesophagitis</td><td>Pleuritic pain flare</td></tr></tbody></table></table-wrap></p></sec><sec id="s0035"><title>Translational research</title><p id="p0260">Patients will be asked to consent to the collection and use of surplus archived formalin-fixed paraffin embedded tumour tissue from their original diagnostic biopsy and to the prospective collection of blood samples at 3 time-points throughout the trial.</p></sec><sec id="s0040"><title>Statistical analysis</title><p id="p0265">The study is designed to detect an absolute increase of 20% in the proportion of responders at week 5 on dose escalated radiotherapy compared to standard radiotherapy from 40% (SYSTEMS <xref rid="b0035" ref-type="bibr">[7]</xref> response rate) to 60%. This requires 112 patients, 56 per arm (comparison of proportions, 90% power, 20% 1-sided level of statistical significance; equivalent to 80% power, 10% level of statistical significance).<list list-type="simple" id="l0025"><list-item id="o0130"><label>&#x02022;</label><p id="p0270">Primary efficacy analysis</p></list-item></list></p><p id="p0275">The benefit of radiotherapy will be assessed by comparing the proportion of responders at 5&#x0202f;weeks between the treatment arms using an adjusted logistic regression model.<list list-type="simple" id="l0030"><list-item id="o0135"><label>&#x02022;</label><p id="p0280">Secondary efficacy analysis</p></list-item></list></p><p id="p0285">Analysis of pain response scores and subscales at weeks 5 and 9 and radiological response at week 9 will use the same approach as the primary efficacy analysis. OS will be compared between the study arms using an adjusted Cox model. A Kaplan-Meier curve will illustrate the relative OS. AUC techniques will be employed to analyse QoL data.<list list-type="simple" id="l0035"><list-item id="o0140"><label>&#x02022;</label><p id="p0290">Safety analysis</p></list-item></list></p><p id="p0295">The worst recorded toxicity grade for each patient will be summarised by study arm and compared using the Mann-Whitney <italic>U</italic> test.<list list-type="simple" id="l0040"><list-item id="o0145"><label>&#x02022;</label><p id="p0300">Interim analysis</p></list-item></list></p><p id="p0305">The study data will be reviewed annually by an independent data monitoring committee. There will be a formal assessment of futility at 50% recruitment. The 3-outcome design <xref rid="b0050" ref-type="bibr">[12]</xref> will determine whether a phase III study is warranted.</p></sec></sec><sec id="s0045"><title>Discussion</title><p id="p0310">Management of MPM associated pain can be complex and often requires a multidisciplinary approach. While chemotherapy is associated with modest survival benefit, there is no evidence that it is helpful for pain <xref rid="b0055" ref-type="bibr">[13]</xref>. Similarly, while surgical procedures can alleviate symptoms such as breathlessness, post thoracotomy pain is common and often difficult to manage <xref rid="b0060" ref-type="bibr">[14]</xref>. Percutaneous cervical cordotomy appears to be beneficial in selected patients, <xref rid="b0065" ref-type="bibr">[15]</xref> but is not widely available and there is no prospective randomised evidence to support its role in MPM.</p><p id="p0315">Palliative radiotherapy can be beneficial for a variety of cancer associated symptoms, particularly bone pain <xref rid="b0070" ref-type="bibr">[16]</xref>. While MPM is generally regarded as radioresistant, palliative doses have long been used to alleviate pain. Nevertheless, the majority of evidence behind this practice is of poor quality, <xref rid="b0030" ref-type="bibr">[6]</xref> and the SYSTEMS study provides the only robust evidence that palliative radiotherapy is clinically beneficial in a substantial proportion of MPM patients <xref rid="b0035" ref-type="bibr">[7]</xref>. The question of whether dose escalation can improve response rates and prolong pain control has been difficult to address because 2-dimentional techniques are ill-suited to delivering high radiotherapy doses to the thoracic cavity. However, recent advances in radiotherapy planning and delivery have enabled dose escalation while maintaining acceptable dose constraints to normal tissues.</p><p id="p0320">We anticipate that SYSTEMS-2 will provide robust and accurate symptom response data for palliative radiotherapy in MPM and help to establish the optimal dose and fractionation in this setting. The generation of toxicity data will provide further information on appropriate OAR dose constraints for hypofractionated regimes, which may help to inform future radiotherapy studies in more common lung cancers. Radiological data will enable further characterisation of radiation responses in MPM and their correlations with clinical outcome. Furthermore, the associated sample collection will create a unique bioresource for future translational research into mesothelioma-specific predictive and response biomarkers, which are urgently required.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Treasure</surname><given-names>T.</given-names></name><name><surname>Lang-Lazdunski</surname><given-names>L.</given-names></name><name><surname>Waller</surname><given-names>D.</given-names></name></person-group><article-title>Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study</article-title><source>Lancet Oncol</source><volume>12</volume><issue>8</issue><year>2011</year><fpage>763</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">21723781</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>de Graaf-Strukowska</surname><given-names>L.</given-names></name><name><surname>van der Zee</surname><given-names>J.</given-names></name><name><surname>van Putten</surname><given-names>W.</given-names></name><name><surname>Senan</surname><given-names>S.</given-names></name></person-group><article-title>Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura&#x02013;a single-institution experience with 189 patients</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>43</volume><issue>3</issue><year>1999</year><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">10078630</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>S.R.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Ball</surname><given-names>D.L.</given-names></name></person-group><article-title>Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation</article-title><source>Australas Radiol</source><volume>38</volume><issue>3</issue><year>1994</year><fpage>212</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">7524472</pub-id></element-citation></ref><ref id="b0020"><label>4</label><mixed-citation publication-type="other" id="h0020">Committee BTSSoC, BTS statement on malignant mesothelioma in the UK, 2007, Thorax. 2007, 62 (Suppl 2), pp. ii1&#x02013;ii19.</mixed-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>MacLeod</surname><given-names>N.</given-names></name><name><surname>Klepstad</surname><given-names>P.</given-names></name><name><surname>Fallon</surname><given-names>M.</given-names></name><name><surname>Laird</surname><given-names>B.</given-names></name></person-group><source>Pain Management in Mesothelioma.</source><volume>5</volume><year>2015</year><fpage>4</fpage></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Macleod</surname><given-names>N.</given-names></name><name><surname>Price</surname><given-names>A.</given-names></name><name><surname>O'Rourke</surname><given-names>N.</given-names></name><name><surname>Fallon</surname><given-names>M.</given-names></name><name><surname>Laird</surname><given-names>B.</given-names></name></person-group><article-title>Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review</article-title><issue-title>Lung Cancer (Amsterdam, Netherlands)</issue-title><volume>83</volume><issue>2</issue><year>2014</year><fpage>133</fpage><lpage>138</lpage></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>MacLeod</surname><given-names>N.</given-names></name><name><surname>Chalmers</surname><given-names>A.</given-names></name><name><surname>O'Rourke</surname><given-names>N.</given-names></name></person-group><article-title>Is radiotherapy useful for treating pain in mesothelioma?: a Phase II trial</article-title><source>J Thoracic Oncol</source><volume>10</volume><issue>6</issue><year>2015</year><fpage>944</fpage><lpage>950</lpage></element-citation></ref><ref id="b9000"><label>8</label><element-citation publication-type="journal" id="h9000"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>C.S.</given-names></name><name><surname>Ryan</surname><given-names>K.M.</given-names></name></person-group><article-title>Pain assessment: global use of the Brief Pain Inventory</article-title><source>Ann Acad Med Singap</source><volume>23</volume><issue>2</issue><year>1994</year><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">8080219</pub-id></element-citation></ref><ref id="b9005"><label>9</label><element-citation publication-type="journal" id="h9005"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>S.</given-names></name><name><surname>Bann</surname><given-names>C.M.</given-names></name><name><surname>Dodd</surname><given-names>S.L.</given-names></name></person-group><article-title>Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain</article-title><source>Clin J Pain</source><volume>20</volume><issue>5</issue><year>2004</year><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">15322437</pub-id></element-citation></ref><ref id="b0040"><label>10</label><mixed-citation publication-type="other" id="h0040">R.D. Timmerman, An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology, Seminars in Radiation Oncology, 18(4), pp. 215&#x02013;222.</mixed-citation></ref><ref id="b0045"><label>11</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Benedict</surname><given-names>S.H.</given-names></name><name><surname>Yenice</surname><given-names>K.M.</given-names></name><name><surname>Followill</surname><given-names>D.</given-names></name></person-group><article-title>Stereotactic body radiation therapy: the report of AAPM Task Group 101</article-title><source>Med Phys</source><volume>37</volume><issue>8</issue><year>2010</year><fpage>4078</fpage><lpage>4101</lpage><pub-id pub-id-type="pmid">20879569</pub-id></element-citation></ref><ref id="b0050"><label>12</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>A three-outcome design for randomized comparative phase II clinical trials</article-title><source>Stat Med</source><volume>26</volume><issue>19</issue><year>2007</year><fpage>3525</fpage><lpage>3534</lpage><pub-id pub-id-type="pmid">17262879</pub-id></element-citation></ref><ref id="b0055"><label>13</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Vogelzang</surname><given-names>N.J.</given-names></name><name><surname>Rusthoven</surname><given-names>J.J.</given-names></name><name><surname>Symanowski</surname><given-names>J.</given-names></name></person-group><article-title>Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma</article-title><source>J Clin Oncol</source><volume>21</volume><issue>14</issue><year>2003</year><fpage>2636</fpage><lpage>2644</lpage><pub-id pub-id-type="pmid">12860938</pub-id></element-citation></ref><ref id="b0060"><label>14</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Gerner</surname><given-names>P.</given-names></name></person-group><article-title>Post-thoracotomy pain management problems</article-title><issue-title>Anesthesiol Clin</issue-title><volume>26</volume><issue>2</issue><year>2008</year><fpage>355</fpage><lpage>vii</lpage></element-citation></ref><ref id="b0065"><label>15</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>M.B.</given-names></name><name><surname>Pounder</surname><given-names>D.</given-names></name><name><surname>Price</surname><given-names>C.</given-names></name><name><surname>Matthews</surname><given-names>A.W.</given-names></name><name><surname>Neville</surname><given-names>E.</given-names></name></person-group><article-title>Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma</article-title><source>Thorax</source><volume>54</volume><issue>3</issue><year>1999</year><fpage>238</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">10325900</pub-id></element-citation></ref><ref id="b0070"><label>16</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.S.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Johnston</surname><given-names>M.</given-names></name><name><surname>Bezjak</surname><given-names>A.</given-names></name><name><surname>Whelan</surname><given-names>T.</given-names></name></person-group><article-title>Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>55</volume><issue>3</issue><year>2003</year><fpage>594</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">12573746</pub-id></element-citation></ref></ref-list><sec id="s0055" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0330"><supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data</title></caption><media xlink:href="mmc1.xml"/></supplementary-material></p></sec><fn-group><fn id="s0050" fn-type="supplementary-material"><label>Appendix A</label><p id="p0325">Supplementary data associated with this article can be found, in the online version, at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ctro.2017.11.004" id="ir005">https://doi.org/10.1016/j.ctro.2017.11.004</ext-link>.</p></fn></fn-group></back></article>